Sydney - Novotech, a leading biotech specialist CRO in the Asia-Pacific region, is sponsoring the ChinaTrials13 conference and will have teams from Novotech’s China offices attending to support biotechs planning clinical trials in China and the Asia-Pacific region (11-21, November 2021). 

The conference brings together China biotechs as well as regional and international firms looking to expedite quality trials.

Of particular focus is oncology research. According to GlobalData, China has the highest incidence of cancer in the world, accounting for 24% of newly diagnosed cases and 30% of cancer-related deaths worldwide in 2020.

Meet the Novotech team at Booth: #11&12

Presentations by Novotech

Workshop: Navigating the Future of Cell Therapies Development: Unlocking the Full Potential

10th November, 9am – 12pm

Qr code

Description automatically generated

Topics include:

  • CAR-T Therapy: Key considerations during clinical development
  • Execution and quality management for cell therapy clinical development
  • Statistical considerations in CAR-T therapy clinical trials

Key Novotech experts along with industry leaders will present, then open up for discussions around key issues. 

Some of the topics covered at the conference include:

  • The Next Phase of Chinese Innovative Biotech Drug Development
  • China+US Development: Should You File Your IND in the US Before/After or Simultaneously Alongside Your China IND?
  • China CMO Roundtable: What's On the Minds of China's Top CMO's?
  • Decentralized Clinical Studies: How COVID-19 Changed Clinical Development & Lessons Learned
  • Regulatory Insights: Taking Advantage of Fast Track Channels
  • MNC Perspectives: China's New Role in Global Development
  • Global Drug Development 2.0: Borderless Innovation
  • Cell & Gene Therapy Drug Development in China: What's Next?
  • Experience Sharing: China Biotech + MNC Pharma Drug Development Partnerships 
  • Digital Technology to Support Remote Inspection to Accelerate Clinical Research: PI, Site and Sponsor Perspectives
  • Choosing the Right Clinical Development Strategy to Optimize Regulatory Approval Pathway
  • Win From the Start: Early Clinical Research Strategies for Innovative Drugs
  • Strategy & Planning of Innovative Drugs in MRCT
  • How to Design Trials to Better Serve the Needs of Clinical & Needs of Patients
  • Strategies for Moving Quickly from Phase I to Phase II
  • Seamless Global Development from Phase I to III: A Tale of COVID-19 Antibody Cocktail Therapy 
  • Real World Data: The Road to Bringing Innovative Therapies to Patients Faster?


1. Home to around 20% of the world’s population, research regulatory reform creates tremendous opportunity for Western biotechs in China - Clinical Trials Arena

 

 關於 Novotech Novotech-CRO.com

Novotech成立於 1997 年,立足亞太,面向全球,是專業的生物技術合同研究組織(CRO)。

Novotech因其在行業內的突出貢獻而備受讚譽,曾榮獲多項殊榮,其中包括 2023 年 CRO 領導力獎 (CRO Leadership Award 2023) 、2023 年亞太地區細胞與基因治療臨床試驗卓越獎 (Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023)和自 2006 年以來蟬聯亞太地區合同研究組織年度公司獎 (Asia-Pacific Contract Research Organization Company of the Year Award)。

Novotech是一家包含實驗室、Ⅰ期臨床中心、藥物開發諮詢服務和專業FDA法規服務的臨床CRO,擁有超5,000 項臨床專案經驗,包括Ⅰ期至Ⅳ期臨床試驗。Novotech專注於服務在亞太、美國與歐洲等地進行臨床試驗的生物技術客戶。Novotech目前在全球34個辦公地點共擁有3000多名員工。

如欲了解更多資訊或與專家團隊成員交談,請造訪 www.Novotech-CRO.com